CY1112162T1 - Αντι-αβ αντισωμα - Google Patents

Αντι-αβ αντισωμα

Info

Publication number
CY1112162T1
CY1112162T1 CY20111101276T CY111101276T CY1112162T1 CY 1112162 T1 CY1112162 T1 CY 1112162T1 CY 20111101276 T CY20111101276 T CY 20111101276T CY 111101276 T CY111101276 T CY 111101276T CY 1112162 T1 CY1112162 T1 CY 1112162T1
Authority
CY
Cyprus
Prior art keywords
abeta
antibody
free
low levels
abeta peptide
Prior art date
Application number
CY20111101276T
Other languages
English (en)
Inventor
Ronald Bradley Demattos
Uma Kuchibhotla
Hsiu-Chiung Yang
Don B Mcclure
Original Assignee
Eli Lilly And Company
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Eli Lilly And Company filed Critical Eli Lilly And Company
Publication of CY1112162T1 publication Critical patent/CY1112162T1/el

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K16/00Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/505Medicinal preparations containing antigens or antibodies comprising antibodies
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K2317/00Immunoglobulins specific features
    • C07K2317/20Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biophysics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Steroid Compounds (AREA)

Abstract

Η παρούσα αυτή εφεύρεση παρέχει μια σύνθεση η οποία είναι κατάλληλη για χορήγηση σε ένα ανθρώπινο υποκείμενο η οποία περιλαμβάνει ένα αντι-Αβ αντίσωμα το οποίο είναι απαλλαγμένο από Αβ πεπτίδιο ή το οποίο έχει αποδεκτώς χαμηλά επίπεδα αυτού, απαλλαγμένο από μη-ανθρώπινο Αβ πεπτίδιο ή το οποίο έχει αποδεκτώς χαμηλά επίπεδα αυτού, ή το οποίο έχει μια μη-ανιχνεύσιμη συγκέντρωση Αβ πεπτιδίου.
CY20111101276T 2004-02-23 2011-12-21 Αντι-αβ αντισωμα CY1112162T1 (el)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US54676404P 2004-02-23 2004-02-23
EP05723280A EP1720909B1 (en) 2004-02-23 2005-02-17 Anti-abeta antibody

Publications (1)

Publication Number Publication Date
CY1112162T1 true CY1112162T1 (el) 2015-12-09

Family

ID=34910810

Family Applications (1)

Application Number Title Priority Date Filing Date
CY20111101276T CY1112162T1 (el) 2004-02-23 2011-12-21 Αντι-αβ αντισωμα

Country Status (20)

Country Link
US (1) US20070190046A1 (el)
EP (1) EP1720909B1 (el)
JP (1) JP4851348B2 (el)
KR (2) KR20090005410A (el)
CN (1) CN1922209B (el)
AT (1) ATE534667T1 (el)
AU (1) AU2005217596B2 (el)
BR (1) BRPI0507856A (el)
CA (1) CA2556436C (el)
CY (1) CY1112162T1 (el)
DK (1) DK1720909T3 (el)
EA (1) EA009872B1 (el)
ES (1) ES2375627T3 (el)
IL (1) IL177611A (el)
NO (1) NO20064239L (el)
PL (1) PL1720909T3 (el)
PT (1) PT1720909E (el)
SI (1) SI1720909T1 (el)
UA (1) UA93181C2 (el)
WO (1) WO2005082939A2 (el)

Families Citing this family (31)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE10303974A1 (de) 2003-01-31 2004-08-05 Abbott Gmbh & Co. Kg Amyloid-β(1-42)-Oligomere, Verfahren zu deren Herstellung und deren Verwendung
PL1954718T3 (pl) 2005-11-30 2015-04-30 Abbvie Inc Przeciwciała skierowane przeciwko A globulomerowi, ich reszty wiążące antygeny, odpowiednie hybrydomy, kwasy nukleinowe, wektory, komórki gospodarze, sposoby wytwarzania tych przeciwciał, kompozycje zawierające te przeciwciała, zastosowania tych przeciwciał i sposoby stosowania tych przeciwciał
DK1976877T4 (en) 2005-11-30 2017-01-16 Abbvie Inc Monoclonal antibodies to amyloid beta protein and uses thereof
CA2632822C (en) 2005-12-12 2018-08-28 Ruth Greferath A beta 1-42 specific monoclonal antibodies with therapeutic properties
AR062065A1 (es) 2006-07-14 2008-10-15 Ac Immune Sa Anticuerpo humanizado
US8455626B2 (en) 2006-11-30 2013-06-04 Abbott Laboratories Aβ conformer selective anti-aβ globulomer monoclonal antibodies
IL199534A (en) 2007-01-05 2013-01-31 Univ Zuerich An isolated human antibody capable of detecting a neoepitope in a disease-related protein, a polynucleotide encoding an antibody, a vector containing the polynucleotide, a host cell containing the polynucleotide or vector, a preparation containing the antibody and related methods and uses.
AU2008203703C1 (en) * 2007-01-05 2014-04-03 University Of Zurich Method of providing disease-specific binding molecules and targets
WO2008084402A2 (en) 2007-01-11 2008-07-17 Philipps-Universitaet Marburg Diagnosis and treatment of alzheimer's and other neurodementing diseases
US20100311767A1 (en) 2007-02-27 2010-12-09 Abbott Gmbh & Co. Kg Method for the treatment of amyloidoses
US8048420B2 (en) 2007-06-12 2011-11-01 Ac Immune S.A. Monoclonal antibody
US8613923B2 (en) 2007-06-12 2013-12-24 Ac Immune S.A. Monoclonal antibody
BRPI0818623A2 (pt) * 2007-10-05 2017-05-23 Ac Immune Sa composição farmacêutica, e, métodos para reduzir a carga da placa na camada de célula de gânglio retinal de um animal, para reduzir a quantidade de placas na camada de célula de gânglio retinal de um animal, para diminuir a quantidade total de amilóide-beta solúvel na camada de célula de gânglio retinal de um animal, para prevenir, tratar e/ou aliviar os efeitos de uma doença ocular associada com anormalidades patológicas/mudanças no tecido do sistema visual, para monitorar doença ocular residual mínima associada com anormalidades patológicas/mudanças nos tecidos do sistema visual, para predizer responsividade de um paciente, e para reter ou diminuir a pressão ocular nos olhos de um animal
US9403902B2 (en) 2007-10-05 2016-08-02 Ac Immune S.A. Methods of treating ocular disease associated with amyloid-beta-related pathology using an anti-amyloid-beta antibody
CA2744043A1 (en) 2008-11-25 2010-06-03 Biogen Idec Ma Inc. Use of dr6 and p75 antagonists to promote survival of cells of the nervous system
CA2746778C (en) 2008-12-19 2019-04-23 University Of Zurich Human anti-alpha-synuclein autoantibodies
RU2012124093A (ru) 2009-11-12 2013-12-20 Дженентек, Инк. Способ увеличения плотности дендритных шипиков
JP2013523182A (ja) 2010-04-15 2013-06-17 アボット・ラボラトリーズ アミロイドベータ結合タンパク質
CA2806909C (en) 2010-07-30 2019-12-17 Ac Immune S.A. Safe and functional humanized antibodies
BR112013004056B8 (pt) * 2010-08-12 2022-10-18 Lilly Co Eli Anticorpos monoclonais ab anti-n3pglu projetados por humano, seu uso e composição farmacêutica que os compreende
EP2603524A1 (en) 2010-08-14 2013-06-19 AbbVie Inc. Amyloid-beta binding proteins
CA2839563C (en) 2011-06-23 2019-10-29 Biogen Idec International Neuroscience Gmbh Anti-alpha synuclein binding molecules
WO2014039781A1 (en) 2012-09-07 2014-03-13 Massachusetts Eye & Ear Infirmary Treating hearing loss
KR102571391B1 (ko) 2013-09-13 2023-08-29 제넨테크, 인크. 정제된 재조합 폴리펩티드를 포함하는 방법 및 조성물
MA41115A (fr) 2014-12-02 2017-10-10 Biogen Int Neuroscience Gmbh Procédé de traitement de la maladie d'alzheimer
CA3024424A1 (en) 2016-05-16 2017-11-23 The General Hospital Corporation Human airway stem cells in lung epithelial engineering
CN109563105A (zh) * 2016-08-11 2019-04-02 伊莱利利公司 氨基噻嗪类化合物及其作为bace1抑制剂的用途
JOP20200041A1 (ar) 2017-08-22 2020-02-20 Biogen Ma Inc تركيبات صيدلية تحتوي على أجسام مضادة لبيتا نشوي
TWI843040B (zh) 2021-01-11 2024-05-21 美商美國禮來大藥廠 抗N3pGlu類澱粉β抗體及其用途
WO2022251048A1 (en) 2021-05-24 2022-12-01 Eli Lilly And Company Anti-amyloid beta antibodies and uses thereof
AU2023216231A1 (en) 2022-02-03 2024-08-01 Eli Lilly And Company Regional tau imaging for diagnosing and treating alzheimer's disease

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2319239T3 (es) 1996-12-23 2009-05-05 Elan Pharmaceuticals, Inc. Cicloalquilo, lactama, lactona y compuestos relacionados, composiciones farmaceuticas que comprenden los mismos y procedimientos para inhibir la liberacion del peptido beta-amiloide y/o sintesis mediante el uso de tales compuestos.
US6518011B1 (en) * 1999-01-13 2003-02-11 Bristol-Myers Squibb Company Method for screening compounds to identify beta-amyloid production modulators
WO2001062801A2 (en) * 2000-02-24 2001-08-30 Washington University Humanized antibodies that sequester amyloid beta peptide
AU2001257022B2 (en) * 2000-04-13 2005-02-03 Mayo Foundation For Medical Education And Research Abeta 42 lowering agents
PE20020574A1 (es) * 2000-12-06 2002-07-02 Wyeth Corp Anticuerpos humanizados que reconocen el peptido amiloideo beta
ES2437875T3 (es) * 2001-04-30 2014-01-14 Eli Lilly And Company Anticuerpos humanizados que reconocen el péptido beta-amiloide

Also Published As

Publication number Publication date
CA2556436C (en) 2014-04-01
WO2005082939A2 (en) 2005-09-09
EP1720909A2 (en) 2006-11-15
AU2005217596A1 (en) 2005-09-09
ATE534667T1 (de) 2011-12-15
EP1720909B1 (en) 2011-11-23
UA93181C2 (ru) 2011-01-25
KR20090005410A (ko) 2009-01-13
CN1922209A (zh) 2007-02-28
WO2005082939A3 (en) 2005-10-27
PT1720909E (pt) 2011-12-23
CN1922209B (zh) 2012-09-05
PL1720909T3 (pl) 2012-04-30
DK1720909T3 (da) 2012-01-30
KR20060126785A (ko) 2006-12-08
CA2556436A1 (en) 2005-09-09
JP2008500279A (ja) 2008-01-10
KR100889430B1 (ko) 2009-03-23
EA200601545A1 (ru) 2007-02-27
EA009872B1 (ru) 2008-04-28
JP4851348B2 (ja) 2012-01-11
IL177611A0 (en) 2006-12-10
BRPI0507856A (pt) 2007-07-10
US20070190046A1 (en) 2007-08-16
ES2375627T3 (es) 2012-03-02
IL177611A (en) 2013-05-30
SI1720909T1 (sl) 2012-01-31
AU2005217596B2 (en) 2012-01-19
NO20064239L (no) 2006-11-20

Similar Documents

Publication Publication Date Title
CY1112162T1 (el) Αντι-αβ αντισωμα
CY1124802T1 (el) Δεσμευτικοι παραγοντες σκληροστινης
AR116860A2 (es) Composición que comprende anticuerpo que se fija al dominio ii de her2, y sus variantes ácidas
CL2012003245A1 (es) Proteína de unión a antígeno aislada que se une a linfopoyetina estromal tímica (tslp); composición que comprende una proteína de unión a antígeno que une tslp correspondiente a un anticuerpo humano anti-tslp.
CO5720212A1 (es) Composicion de anticuerpo her2
DK3530673T3 (da) Humaniserede anti-beta7-antagonister og anvendelser deraf
CU24058B1 (es) Antagonistas de pcsk9
EA201991701A1 (ru) Состав на основе моноклонального антитела к rsv
EA200700702A1 (ru) Аналоги локсапина и способы их применения
TR201901841T4 (tr) Her antikorlarının sabit dozlaması.
EA200800812A1 (ru) Композиции антитела против cd3
CL2011000010A1 (es) Anticuerpo monoclonal anti-peptido beta-amiloide; polinucleotido que lo codifica; hibridoma; metodo de produccion; composicion que lo comprende; uso para tratar enfermedades relacionadas con proteinas amiloides; metodo de diagnostico de las mismas; y kit que lo comprende.
EA200700175A1 (ru) Композиции и способы лечения воспалительных заболеваний
MEP35408A (en) Tweak binding antibodies
EA200702008A1 (ru) Антитела-нейтрализаторы гранулоцитарно-макрофагального колониестимулирующего фактора человека
ATE553778T1 (de) Für humanes hepcidin spezifische antikörper
ATE550354T1 (de) Humane ringspezifische bnp-antikörper
MA33210B1 (fr) Nouveaux anticorps anti-a5b1 et leurs utilisations
EA200800601A1 (ru) Связывающие fas антитела
EA200601743A1 (ru) Выделенный полипептид реналазы и его применение
RU2010100549A (ru) Способ получения n-(1,3,5-дитиазинан-5-ил)-изоникотинамида и n-(2,4,6-триметил-1,3,5-дитиазинан-5-ил)-изоникотинамида
ATE417849T1 (de) Pyrazoloä4,3-düpyrimidine
CO6382184A2 (es) Proteinas fijadoras de receptores de interleukinas-21
ATE527354T1 (de) Diabetogene epitope
CY1113832T1 (el) Μεθοδος για την στερεοεκλεκτικη παρασκευη (-)-halofenate και παραγωγων αυτης